Literature DB >> 22461245

Implementing adherence to osteoporosis treatments.

Stefano Gonnelli1, Laura Masi, Maria Luisa Brandi, Ranuccio Nuti.   

Abstract

At present chronic diseases are of crucial importance for all health services in the Western World for both their epidemic prevalence and the fact that they absorb a growing proportion of health service financial resources. Osteoporosis has clinical and public health importance because osteoporotic fractures are one of the most common causes of disability and an important contributor to medical costs in many regions of the world Increased longevity has resulted in the emergence of age-related fragility fractures as a major public health problem. Today several classes of effective drugs are available for osteoporosis. However, these drugs to be effective, need to be taken long-term. In the case of BPs data have shown that nearly 70% of patients on a daily, and almost 60% on a weekly treatment, stop taking medication before the end of 1 year. A poor adherence is associated to an increased probability of fractures with consequent higher likelihood of hospitalisation and higher costs. Since reasons for nonadherence may depend on individual beliefs and circumstances the strategy to improve adherence should be tailored according to the individual patient. These findings underline the key role played by the physicians, above all GPs, in a strategy to improve adherence which now could be supported by the avaibility of new drugs and innovative administration routes.

Entities:  

Year:  2009        PMID: 22461245      PMCID: PMC2811349     

Source DB:  PubMed          Journal:  Clin Cases Miner Bone Metab        ISSN: 1724-8914


  30 in total

1.  Incorporating adherence into health economic modelling of osteoporosis.

Authors:  O Ström; F Borgström; J A Kanis; B Jönsson
Journal:  Osteoporos Int       Date:  2008-06-03       Impact factor: 4.507

2.  Costs and quality of life associated with osteoporosis-related fractures in Sweden.

Authors:  Fredrik Borgström; Niklas Zethraeus; Olof Johnell; Lars Lidgren; Sari Ponzer; Olle Svensson; Peter Abdon; Ewald Ornstein; Karl Lunsjö; Karl Göran Thorngren; Ingemar Sernbo; Clas Rehnberg; Bengt Jönsson
Journal:  Osteoporos Int       Date:  2005-11-09       Impact factor: 4.507

3.  Adherence with osteoporosis practice guidelines: a multilevel analysis of patient, physician, and practice setting characteristics.

Authors:  Daniel H Solomon; M Alan Brookhart; Tejal K Gandhi; Andrew Karson; Soheyla Gharib; E John Orav; Shimon Shaykevich; Andrea Licari; Danielle Cabral; David W Bates
Journal:  Am J Med       Date:  2004-12-15       Impact factor: 4.965

4.  The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.

Authors:  Colleen A McHorney; John T Schousboe; Richard R Cline; Thomas W Weiss
Journal:  Curr Med Res Opin       Date:  2007-12       Impact factor: 2.580

Review 5.  Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review.

Authors:  T Gleeson; M D Iversen; J Avorn; A M Brookhart; J N Katz; E Losina; F May; A R Patrick; W H Shrank; D H Solomon
Journal:  Osteoporos Int       Date:  2009-06-05       Impact factor: 4.507

6.  Compliance with pharmacologic therapy for osteoporosis.

Authors:  Robert A Yood; Srinivas Emani; John I Reed; Barbara Edelman Lewis; Mary Charpentier; Eva Lydick
Journal:  Osteoporos Int       Date:  2003-09-19       Impact factor: 4.507

7.  Early discontinuation of treatment for osteoporosis.

Authors:  Anna N A Tosteson; Margaret R Grove; Cristina S Hammond; Megan M Moncur; G Thomas Ray; Gwen M Hebert; Alice R Pressman; Bruce Ettinger
Journal:  Am J Med       Date:  2003-08-15       Impact factor: 4.965

8.  Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence.

Authors:  C Roerholt; P Eiken; B Abrahamsen
Journal:  Osteoporos Int       Date:  2008-06-13       Impact factor: 4.507

9.  Cost effectiveness of an adherence-improving programme in hypertensive patients.

Authors:  Danielle E M Brunenberg; Gwenn E C Wetzels; Patricia J Nelemans; Carmen D Dirksen; Johan L Severens; Henri E J H Stoffers; Jan S A G Schouten; Martin H Prins; Peter W de Leeuw; Manuela A Joore
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.558

10.  Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study.

Authors:  A Cooper; J Drake; E Brankin
Journal:  Int J Clin Pract       Date:  2006-06-19       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.